Tag: Amgen

Romosozumab receives approval in Japan for treatment of osteoporosis in patients...

The Japanese Ministry of Health, Labor and Welfare has granted a marketing authorisation for EVENITY (romosozumab; Amgen and UCB) for the treatment of osteoporosis...

FDA advisory committee to review Evenity (romosozumab) for the treatment of...

The US Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) are to review data supporting the Biologics License Application...

European Commission approves Prolia for patients with glucocorticoid-induced osteoporosis

Amgen has announced that the European Commission (EC) has approved a new indication for Prolia (denosumab) for the treatment of bone loss associated with long-term systemic...

Romosozumab leads to significant bone mineral density gains at lumbar spine...

UCB and Amgen have announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the investigational agent romosozumab resulted in...